Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Other 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Polycystic Ovary Syndrome 1Obesity 1Fatty Liver 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × penclomedine × Clear all
NCT02157974 2024-06-04

APPLE

University of Colorado, Denver

Phase 2/3 Completed
92 enrolled 17 charts
Other

Fatty Liver, Obesity, Polycystic Ovary Syndrome

NCT00002915 2010-08-09

Penclomedine in Treating Patients With Advanced Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡